Emavusertib, a selective IRAK-4 inhibitor, is under clinical investigation to overcome the persistent survival signaling through IRAK-4 in B-cell lymphomas [238]. The gene discussed is IRAK4; the disease is B-cell non-Hodgkin lymphoma.